308 related articles for article (PubMed ID: 15011897)
1. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Suwanawiboon B; Sumida KN
Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
[TBL] [Abstract][Full Text] [Related]
2. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
3. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
[TBL] [Abstract][Full Text] [Related]
4. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
Demakos EP; Linebaugh JA
Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
[TBL] [Abstract][Full Text] [Related]
5. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
6. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
10. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
11. Managing patients with low-risk MDS.
Sekeres M; Cosgrove D; Falco A
Clin Adv Hematol Oncol; 2006 Jul; 4(7 Suppl 16):1-10; quiz 11-2. PubMed ID: 17139240
[TBL] [Abstract][Full Text] [Related]
12. Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Sayar H; Chan RJ; Orschell CM; Chan EM; Yu Z; Hood D; Plett A; Yang Z; Hui CL; Nabinger SC; Kohlbacher KJ; West ES; Walter A; Sampson C; Wu J; Cripe LD
Leuk Res; 2011 Aug; 35(8):1108-10. PubMed ID: 21420732
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors in myelodysplastic syndromes.
Blinder VS; Roboz GJ
Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
[TBL] [Abstract][Full Text] [Related]
14. Azacitidine in lower-risk myelodysplastic syndromes.
Santini V
Leuk Res; 2009 Dec; 33 Suppl 2():S22-6. PubMed ID: 20004794
[TBL] [Abstract][Full Text] [Related]
15. Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML
Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
17. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
18. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
19. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Cazzola M
Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
[TBL] [Abstract][Full Text] [Related]
20. Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.
Becherer K; Golda N; Feldman M; Diaz-Arias A; Caldwell C
J Cutan Pathol; 2009 Sep; 36(9):1024-6. PubMed ID: 19674208
[No Abstract] [Full Text] [Related]
[Next] [New Search]
